Many newly developed active pharmaceutical ingredients (APIs) are poor water-soluble what often results in a very low bioavailability of these substances. To overcome this issue, an appropriate formulation strategy is necessary. An approach could be e.g. a strong particle size reduction of the API into nanoparticles by milling or a formulation of the substances in lipid nanodispersions. Which strategy is most appropriate depends on the physical and chemical properties of the API under investigation and has to be evaluated.
Besides the formulation strategy of the API, its final dosage form should also be considered during formulation development. Studies indicated that a successful therapy strongly depends on a regular intake of the medication by the patient and thus, a high level of acceptance. While a formulation for peroral use is preferred by most people, not all can swallow a tablet or capsule as a whole. Especially children, elderly or patients with swallowing problems often struggle when they have to take one monolithic dosage form. Therefore, a more innovative and patient-oriented formulation that also considers a more individualized dosage of the API is necessary to ensure a successful therapy.
In my group we are focusing on the following research areas:
- Formulation of poorly water-soluble APIs using nanoparticular systems like e.g. lipid carriers
- Embedding of liquid formulations in solid matrixes
- Formulation of innovative dosage forms such as orodispersible films
- Development of strategies for an individualization of solid dosage forms
- Investigations of an alternative processes for the preparation of lipid nanodispersions